AJANTA PHARMA LTD
GenericsAJANTA PHARMA LTD is a generic drug manufacturer focused on Neurology, Cardiovascular, Gastroenterology.
AJANTA PHARMA LTD's Key Drugs
AJANTA PHARMA LTD's core commercial portfolio centers on NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, AMLODIPINE AND OLMESARTAN MEDOXOMIL, SITAGLIPTIN AND METFORMIN HYDROCHLORIDE, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
AJANTA PHARMA LTD's Recent FDA Approvals
AJANTA PHARMA LTD secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AJANTA PHARMA LTD's Therapeutic Areas
AJANTA PHARMA LTD's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AJANTA PHARMA LTD's Top Competitors
AJANTA PHARMA LTD's closest competitors by therapeutic-area and drug-target overlap include AbbVie, WARNER CHILCOTT, and B BRAUN. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AJANTA PHARMA LTD Pipeline Snapshot
Active clinical trials for AJANTA PHARMA LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NAPROXEN AND ESOMEPRAZOLE MAGNESIUM leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (1)
Company Info
- First Approval
- 2011-08-24
- Latest
- 2026-04-07
- Applications
- 79